Pharmacy

Your Article Summary

See Latest Articles

Bayer Schering Pharma presents positive results of phase II study with Riociguat
BayNews International, 05/20/09

Positive data from a phase II trial with Bayer Schering Pharma's oral agent riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension were presented today at the American Thoracic Society international conference in San Diego, USA. Riociguat is the first member of a new class of vasodilating agents called soluble guanylate cyclase stimulators and is being investigated as a new approach for the treatment of different forms of pulmonary hypertension.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Human genome sciences announces results of randomized phase 2 trial of mapatumumab in non-small cell lung cancer
Human Genome Sciences, 03/18/10

Boston Scientific Completes Enrollment in PLATINUM Trials for Small Vessels and Long Lesions
Boston Scientific, 03/17/10

Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients
Novartis, 03/17/10

 See all of Drug Trials

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

Efficacy and Safety of Levetiracetam in Patients With Glioma: A Clinical Prospective Study
Archives of Neurology, 03/12/10

A pilot study to evaluate a community pharmacy–based monitoring system to identify adverse drug reactions associated with paediatric medicines use
European Journal of Clinical Pharmacology, 03/05/10

Disease-modifying antirheumatic drugs prove most cost-effective in very early RA
Formulary , 03/02/10

 See all of Major Studies